Solventum (SOLV) Stock Fair Value Rises After Q2 And HIS Separation Plans

Solventum’s analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment aligns with recent analyst commentary that points to Q2 results, the planned Health Information Systems separation, and views on the company’s MedTech focus as reasons to revisit price targets. Read on to see how these factors shape the evolving Solventum narrative and what to watch as new data comes in. Analyst Price Targets don't always capture...